Pfizer integrates Chai Discovery’s AI platform to advance and scale molecular drug design
Alyssa Davidson
Posted: June 5, 2026 10:30 AM Updated: June 5, 2026 9:57 AM
Correction and fact check date: June 5, 2026, 10:30 AM
briefly
Chai Discovery has signed a licensing agreement with Pfizer to deploy AI models in drug discovery, enabling faster molecular design, improved antibody development, and broader biologics research capabilities.
Chai Discovery, a company that develops artificial intelligence models for molecular discovery, announced that it has signed a licensing agreement with pharmaceutical company Pfizer.
The company is focused on applying AI to drug discovery to reduce reliance on traditional trial and error methods. The models are designed to analyze biological structure and function, generate new molecular candidates, and support pharmaceutical research on targets that are difficult to address using traditional approaches.
Under the agreement, Pfizer will integrate Chai’s AI platform into its drug discovery workflow, providing early access to the Chai-3 model as well as a customized version that is trained on Pfizer’s proprietary data and applied to internal processes.
Chai Discovery develops generative AI systems that can predict and engineer molecular interactions, enabling the design of biomolecules with specific functional properties. Drug discovery has historically involved long experimental cycles with uncertain outcomes, but advanced AI models can accelerate early-stage research by generating new molecular structures and shortening development timelines from months or years to shorter iterative cycles.
The Chai-3 model improves antibody design performance and discovery speed.
According to the announcement, the combination of Chai’s AI platform and Pfizer’s scientific expertise and proprietary data sets is expected to expand the capabilities of biological research and support efforts to pursue previously challenging therapeutic targets.
As part of this agreement, Pfizer will be the first pharmaceutical partner to gain access to Chai-3, a previously unreleased model. This system is reported to offer significant improvements in AI-based antibody design, including higher success rates and the ability to generate antibodies that meet therapeutic requirements compared to previous versions. It also improves performance in areas such as multispecific molecules, difficult-to-target proteins, and generalization across biological tasks.
Chai-3 is a zero-shot antibody design system capable of generating drug-like candidates with significantly improved experimental success rates compared to previous computational methods, building on the company’s initial Chai-2 model introduced in 2025, shortening the discovery period from months to weeks.
The agreement between Chai Discovery and Pfizer reflects a broader trend of increasing adoption of advanced AI systems within the pharmaceutical industry as the technology moves from experimental research to integration within established drug development pipelines.
disclaimer
In accordance with the Trust Project Guidelines, the information provided on these pages is not intended and should not be construed as legal, tax, investment, financial or any other form of advice. It is important to invest only what you can afford to lose and, when in doubt, seek independent financial advice. We recommend that you refer to the Terms of Use and help and support pages provided by the publisher or advertiser for more information. Although MetaversePost is committed to accurate and unbiased reporting, market conditions may change without notice.
About the author
As a dedicated journalist at MPost, Alisa specializes in the broad areas of cryptocurrency, AI, investing, and Web3. With a keen eye for new trends and technologies, she provides comprehensive coverage to inform and engage readers about the ever-evolving digital financial landscape.
more articles
As a dedicated journalist at MPost, Alisa specializes in the broad areas of cryptocurrency, AI, investing, and Web3. With a keen eye for new trends and technologies, she provides comprehensive coverage to inform and engage readers about the ever-evolving digital financial landscape.
more articles